Double blind trial of bezafibrate in familial hypercholesterolaemia.
A six month, double blind, crossover controlled trial of bezafibrate was conducted in 14 children with familial hypercholesterolaemia all of whom had a strong family history of early coronary heart disease. The bezafibrate was given twice daily in a dose of 10 to 20 mg/kg/day. The mean plasma total cholesterol concentration on bezafibrate was 22% lower than during the period on placebo and there was a moderate rise in high density lipoprotein cholesterol. Bezafibrate may be a useful adjunct to treatment in these children.
D000293:Adolescent; D001629:Bezafibrate / Q000627:therapeutic use* / Q000652:urine; D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D014280:Triglycerides / Q000097:blood
D008075:Lipoproteins, HDL; D014280:Triglycerides; D002784:Cholesterol; D001629:Bezafibrate